ArticleNuclear medicine and biology2014
Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).
Article in Nuclear medicine and biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.Molecules (Basel, Switzerland) · 2023Review
- Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.European journal of nuclear medicine and molecular imaging · 2022Review
- An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications.Pharmaceutics · 2022Article
- Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.Journal of clinical medicine · 2020Review
- Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives.Molecular imaging and biology · 2020Article
- A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.Bioorganic & medicinal chemistry · 2020Article
- Article
- Development and Evaluation of anMolecular pharmaceutics · 2019Article
- Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells.ACS applied materials & interfaces · 2019Article
- In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.Chemistry (Weinheim an der Bergstrasse, Germany) · 2017Article
- Rapid PD-L1 detection in tumors with PET using a highly specific peptide.Biochemical and biophysical research communications · 2017Article
- [EJNMMI radiopharmacy and chemistry · 2017Article
- Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas.Nuclear medicine and biology · 2016Article
- Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis.ACS nano · 2016Article
- A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.Oncotarget · 2016Article
- Al[18F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression.Molecular imaging and biology · 2016Article
- Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.Molecular pharmaceutics · 2015Article
- Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.Theranostics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Over-expression of chemokine receptor 4 (CXCR4) is present in a majority of cancers, has been linked to an aggressive phenotype, and may indicate the metastatic potential of primary tumor. Several CXCR4 targeted therapeutics are in clinical trials and the development of the corresponding imaging agents is an area of active interest. Previously, (64)Cu-labeled imaging agents for CXCR4 have provided clear images of CXCR4-bearing tissues in relevant experimental models but demonstrated fast washout from tissues harboring receptor. Addition of stabilizing bridges is known to provide more robust chelator-Cu(II) complexes. In addition, bridged cyclam-based CXCR4 binding agents demonstrated increased receptor residence times relative to existing agents. Based on that knowledge we synthesized several bridged cyclam analogs of AMD3465, a monocyclam-based CXCR4 imaging agent, to increase the retention time of the tracer bound to the receptor to allow for protracted imaging and improved target-to-non-target ratios. Specific accumulation of two radiolabeled, cross-bridged analogs ([(64)Cu] RAD1-24 and [(64)Cu]RAD1-52) was observed in U87-stb-CXCR4 tumors in both PET/CT imaging and biodistribution studies. At 90min post-injection of radiotracer, tumor-to-muscle and tumor-to-blood ratios reached 106.05±17.19 and 28.08±4.78, respectively, for cross-bridged pyrimidine analog [(64)Cu]RAD1-52. Receptor blockade performed in vivo denoted target binding specificity. The biodistribution and PET/CT imaging studies with the radiolabeled bridged cyclams demonstrated longer tumor retention and comparable uptake to [(64)Cu]AMD3465, though [(64)Cu]AMD3465 demonstrated superior overall pharmacokinetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.